• Je něco špatně v tomto záznamu ?

Allantoin as a marker of oxidative stress in human erythrocytes

R Kand'ar, P Zakova

. 2008 ; 46 (9) : 1270-1274.

Jazyk angličtina Země Německo

Perzistentní odkaz   https://www.medvik.cz/link/bmc11004987

BACKGROUND: Uric acid is the final product of purine metabolism in humans. It was determined that this compound has important antioxidative properties and it may be oxidized to allantoin by various reactive oxygen species. Therefore, the measurement of allantoin may be useful for the determination of oxidative stress in humans. METHODS: We measured allantoin and uric acid in human plasma and erythrocytes obtained from patients with chronic renal failure before hemodialysis (n=30) and blood donors (n=30). We used a method based on selective isolation of allantoin from deproteinized plasma and erythrocyte lysate samples on AG 1-X8 resin and its derivatization to glyoxylate-2, 4-dinitrophenylhydrazone. Separation of glyoxylate-2, 4-dinitrophenylhydrazone from interfering substances was achieved on reversed phase HPLC with gradient elution and UV/VIS detection at 360 nm. Uric acid was determined by reversed phase HPLC with UV/VIS detection at 292 nm. RESULTS: We found significant differences in allantoin and uric acid concentration between the patients with chronic renal failure and the control group both in plasma (20.5+/-6.5 micromol/L and 323.9+/-62.9 micromol/L vs. 2.1+/-1.1 micromol/L and 270.1+/-62.3 micromol/L, p<0.05) and erythrocytes [82.8+/-39.1 nmol/g hemoglobin (Hb) and 110.7+/-28.8 nmol/g Hb vs. 20.1+/-6.1 nmol/g Hb and 82.1+/-23.7 nmol/g Hb, p<0.05]. CONCLUSIONS: Significant higher levels of allantoin in both plasma and erythrocytes of patients with chronic renal failure indicate that allantoin may be used as a good marker of oxidative stress.

000      
01736naa 2200385 a 4500
001      
bmc11004987
003      
CZ-PrNML
005      
20121030115148.0
008      
110311s2008 gw e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kanďár, Roman $7 stk2007405945
245    10
$a Allantoin as a marker of oxidative stress in human erythrocytes / $c R Kand'ar, P Zakova
314    __
$a Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic. roman.kandar@upce.cz
520    9_
$a BACKGROUND: Uric acid is the final product of purine metabolism in humans. It was determined that this compound has important antioxidative properties and it may be oxidized to allantoin by various reactive oxygen species. Therefore, the measurement of allantoin may be useful for the determination of oxidative stress in humans. METHODS: We measured allantoin and uric acid in human plasma and erythrocytes obtained from patients with chronic renal failure before hemodialysis (n=30) and blood donors (n=30). We used a method based on selective isolation of allantoin from deproteinized plasma and erythrocyte lysate samples on AG 1-X8 resin and its derivatization to glyoxylate-2, 4-dinitrophenylhydrazone. Separation of glyoxylate-2, 4-dinitrophenylhydrazone from interfering substances was achieved on reversed phase HPLC with gradient elution and UV/VIS detection at 360 nm. Uric acid was determined by reversed phase HPLC with UV/VIS detection at 292 nm. RESULTS: We found significant differences in allantoin and uric acid concentration between the patients with chronic renal failure and the control group both in plasma (20.5+/-6.5 micromol/L and 323.9+/-62.9 micromol/L vs. 2.1+/-1.1 micromol/L and 270.1+/-62.3 micromol/L, p<0.05) and erythrocytes [82.8+/-39.1 nmol/g hemoglobin (Hb) and 110.7+/-28.8 nmol/g Hb vs. 20.1+/-6.1 nmol/g Hb and 82.1+/-23.7 nmol/g Hb, p<0.05]. CONCLUSIONS: Significant higher levels of allantoin in both plasma and erythrocytes of patients with chronic renal failure indicate that allantoin may be used as a good marker of oxidative stress.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a alantoin $x krev $7 D000481
650    _2
$a antioxidancia $x metabolismus $7 D000975
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a erytrocyty $x metabolismus $7 D004912
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a oxidační stres $7 D018384
650    _2
$a kyselina močová $x krev $7 D014527
650    _2
$a financování organizované $7 D005381
700    1_
$a Žáková, Pavla, $d 1977- $7 xx0094681
773    0_
$t Clinical Chemistry & Laboratory Medicine $w MED00010886 $g Roč. 46, č. 9 (2008), s. 1270-1274 $x 1434-6621
910    __
$a ABA008 $b x $y 1
990    __
$a 20110414093937 $b ABA008
991    __
$a 20121030115151 $b ABA008
999    __
$a ok $b bmc $g 832857 $s 697027
BAS    __
$a 3
BMC    __
$a 2008 $b 46 $c 9 $d 1270-1274 $i 1434-6621 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
LZP    __
$a 2011-4B/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace